BOMAC C.B.G. 375 METABOLIC TREATMENT FOR CATTLE

Main information

  • Trade name:
  • BOMAC C.B.G. 375 METABOLIC TREATMENT FOR CATTLE
  • Class:
  • Veterinary Medicine
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • BOMAC C.B.G. 375 METABOLIC TREATMENT FOR CATTLE
    Australia
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • CATTLE | BEEF | BOS INDICUS | BOS TAURUS | BOVINE | BUFFALO | BULL | BULLOCK | CALF | COW | DAIRY COW | HEIFER | STEER
  • Therapeutic area:
  • NUTRITION & METABOLISM
  • Therapeutic indications:
  • METABOLIC TREATMENT

Other information

Status

  • Source:
  • Australian Pesticides and Veterinary Medicines Authority (APVMA)
  • Authorization status:
  • Registered
  • Authorization number:
  • 36030
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

MATERIAL SAFETY DATA SHEET (MSDS)

BOMAC Laboratories Limited urges recipient of this MSDS to study it carefully

to become aware of, and understand, the hazards associated with the product.

To promote safe handling, each recipient should notify its employees, agents and others

who will use this material and any other information regarding hazards or safety.

IDENTIFICATION

Product Name: C.B.G 37.5 UN Number : Free

Other Names: N/A Dangerous Goods Class N/A

Animal Remedies Board (ARB) Subsidiary Risk: N/A

Product Licence Number: 4633 HAZCHEM Code: N/A

Toxic Substances Schedule: N/A

Use: For the treatment of milk fever in cattle.

Physical Description: A clear solution, practically colourless and odourless.

Active Ingredients: Calcium Borogluconate CAS* No. 5743-34-0 375g/Litre

Manufacturer: BOMAC Laboratories Ltd

Cnr Wiri Station Road & Hobill Avenue

P O Box 76-369, Manukau City, Auckland, New Zealand

Phone: (09) 262-3169 Fax: (09) 262-3008

Distributor:PharmTech Pty Ltd

8 Apollo Ave,West Pymble NSW 2073 Australia

Phone: 0500 886 668 Facsimile 0500 886 669

HEALTH HAZARD INFORMATION

HEALTH EFFECTS

Swallowed: May cause vomiting and diarrhoea, an erythematous rash followed by desquamation, and

stimulation of the nervous system followed by depression.

Eye: May causetransient stinging or redness.

*CAS, Chemical Abstracts Service Registry Number

Skin: Product is not considered to be a skin irritant.

Inhaled: No inhalation hazard identified from data found.

FIRST AID

Swallowed: Induce vomiting. Seek medical advice.

Eye: Flush out with a gentle stream of clean water for 15 minutes. Seek medical advice if stinging or

redness persists.

Skin: Wash contact areas with water. Remove contaminated clothing and launder before reuse.

Inhalation: Remove from further exposure.If unconsciousness occurs, seek immediate medical

attention. If breathing has stopped, use mouth to mouth resuscitation.

PRECAUTIONS FOR USE

Exposure Limits: Not established. Use only as directed.

Ventilation: No special ventilation is recommended under normal conditions of use. No special

respiratory protection equipment is recommended under normal conditions of use with sufficient

ventilation.

Personal Protection: Avoid eye and skin contact.Wear eye protection (face visor or goggles) if

accidental eye contact can occur. Observe good personal hygiene.

Flammability: Non flammable. Keep well away from heat and keep container closed when not in use.

SAFE HANDLING INFORMATION

Storage and Transport: Store below 25°C.Protect from light. Containers should always be kept

closed in storage. Store only in original containers. Keep out of reach of children. Any solution

remaining in the bag following withdrawal of the required dose should be discarded.

PRODUCT: C.B.G 37.5 ARB Product Licence No: 4633 Page 3 of 3

Spills and Disposal: Remove with liquid binding material (eg sand, sawdust, or diatomaceous earth).

Wash the residue from the contaminated area with water. Dispose of waste in compliance with local

waste disposal regulations. Small quantities and residues may be flushed into drains.

Fire/Explosion Hazard: The product is non flammable. Use alcohol foam, CO2, dry powder, water or

BCF fire extinguishers. Use water sprays to cool fire exposed surfaces and any adjacent storage

vessels.

Sheet Dated: 31 January 1996 Supersedes Sheet Dated: 07 November 1995

Contact Point:

Distributor:PharmTech Pty Ltd

8 Apollo Ave,West Pymble NSW 2073 Australia

Phone: 0500 886 668 Facsimile 0500 886 669

Or Dr Bruce Vautier B.V.Sc

Manager, Technical Services

BOMAC Laboratories Ltd

CnrWiri Station Road & Hobill Avenue

PO Box 76-369, Manukau City, Auckland,

New Zealand

Phone: (09) 262-3169

Facsimile: (09) 262-3008

Additional Information:

National Poisons Information Centre OR Contact your local Poisons

University of Otago, Medical School Information Centre for

PO Box 913 further advice.

Dunedin

New Zealand

Phone (03) 474 700

The information in this data sheet is to the best of our knowledge, representative of the product. As

conditions of use are beyond the control of BOMAC Laboratories Ltd no legal responsibility is

accepted for the use of this information.

7-12-2018

Magnesium citrate malate as a source of magnesium added for nutritional purposes to food supplements

Magnesium citrate malate as a source of magnesium added for nutritional purposes to food supplements

Published on: Thu, 06 Dec 2018 The present scientific opinion deals with the assessment of the bioavailability of magnesium, from the proposed nutrient source, magnesium citrate malate (MgCM), when added for nutritional purposes to food supplements. MgCM is a mixed salt consisting of magnesium cations and citrate and malate anions, and with a magnesium content of 12–15%. MgCM is proposed to be used in food supplements that are intended to provide up to 300–540 mg/day magnesium. The data provided demonst...

Europe - EFSA - European Food Safety Authority Publications

29-8-2018

Modification of the existing maximum residue levels for prohexadione in various oilseeds

Modification of the existing maximum residue levels for prohexadione in various oilseeds

Published on: Mon, 27 Aug 2018 00:00:00 +0200 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicant BASF SE submitted a request to the competent national authority in France to modify the existing maximum residue levels (MRL) for the active substance prohexadione in linseeds, poppy seeds, sunflower seeds, rape seeds, mustard seeds and gold of pleasure seeds. The data submitted in support of the request were found to be sufficient to derive MRL proposals for all oilseeds under consid...

Europe - EFSA - European Food Safety Authority Publications

19-12-2008

Consultation responses on the future reimbursement status of dihydropyridine calcium antagonists (C08CA)

Consultation responses on the future reimbursement status of dihydropyridine calcium antagonists (C08CA)

The Danish Medicines Agency's assessment of the future reimbursement status of the dihydropyridine calcium antagonists (C08CA) were submitted for consultation with 11 November 2008 as the consultation deadline.

Danish Medicines Agency

29-10-2008

Reassessment of reimbursement status for medicinal products in ATC group C08CA

Reassessment of reimbursement status for medicinal products in ATC group C08CA

The Danish Medicines Agency has assessed the question of the future reimbursement status for medicinal products in ATC group C08CA (dihydropyridine calcium channel blockers) which are used for the treatment of cardiovascular diseases.

Danish Medicines Agency

8-9-2008

Reassessment of reimbursement status of medicinal products for cardiovascular diseases – additional recommendation from the Reimbursement Committee

Reassessment of reimbursement status of medicinal products for cardiovascular diseases – additional recommendation from the Reimbursement Committee

The Danish Medicines Agency has asked the Reimbursement Committee to reassess the reimbursement status of medicinal products authorised for marketing in Denmark in the ATC groups C02 (antihypertensives), C03 (diuretics), C07 (beta blocking agents), C08 (calcium channel blockers) and C09 (ACE inhibitors, angiotensin II antagonists and renin inhibitors).

Danish Medicines Agency

14-2-2008

Reassessment of reimbursement status for medicinal products for the treatment of cardiovascular diseases

Reassessment of reimbursement status for medicinal products for the treatment of cardiovascular diseases

Following a request from the Danish Medicines Agency, the Reimbursement Committee has reassessed the reimbursement status for medicinal products authorised for marketing in Denmark in ATC groups C02 (antihypertensives), C03 (diuretics), C07 (beta blocking agents), C08 (calcium channel blockers) and C09 (ACE inhibitors, angiotensin II antagonists and renin inhibitors).

Danish Medicines Agency

18-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): Omega-3-acid ethyl esters 90 / rosuvastatin (calcium), decision type: , therapeutic area: , PIP number: P/0309/2018

Opinion/decision on a Paediatric investigation plan (PIP): Omega-3-acid ethyl esters 90 / rosuvastatin (calcium), decision type: , therapeutic area: , PIP number: P/0309/2018

Opinion/decision on a Paediatric investigation plan (PIP): Omega-3-acid ethyl esters 90 / rosuvastatin (calcium), decision type: , therapeutic area: , PIP number: P/0309/2018

Europe - EMA - European Medicines Agency

18-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): Acetylsalicylic acid / rosuvastatin (calcium) / perindopril (tert-butylamine) / indapamide (hemihydrate), decision type: , therapeutic area: , PIP number: P/0311/2018

Opinion/decision on a Paediatric investigation plan (PIP): Acetylsalicylic acid / rosuvastatin (calcium) / perindopril (tert-butylamine) / indapamide (hemihydrate), decision type: , therapeutic area: , PIP number: P/0311/2018

Opinion/decision on a Paediatric investigation plan (PIP): Acetylsalicylic acid / rosuvastatin (calcium) / perindopril (tert-butylamine) / indapamide (hemihydrate), decision type: , therapeutic area: , PIP number: P/0311/2018

Europe - EMA - European Medicines Agency

18-12-2018


Calcium chloride / glutamic acid / glutathione / histidine / lactobionic acid / magnesium chloride / mannitol / potassium chloride / sodium hydroxide: List of nationally authorised medicinal products - PSUSA/00010390/201801

Calcium chloride / glutamic acid / glutathione / histidine / lactobionic acid / magnesium chloride / mannitol / potassium chloride / sodium hydroxide: List of nationally authorised medicinal products - PSUSA/00010390/201801

Calcium chloride / glutamic acid / glutathione / histidine / lactobionic acid / magnesium chloride / mannitol / potassium chloride / sodium hydroxide: List of nationally authorised medicinal products - PSUSA/00010390/201801

Europe - EMA - European Medicines Agency

14-12-2018


Referral: Fosfomycin-containing medicinal products, fosfomycin calcium, fosfomycin disodium, fosfomycin sodium, fosfomycin trometamol, Article 31 referrals, Procedure started, 13/12/2018

Referral: Fosfomycin-containing medicinal products, fosfomycin calcium, fosfomycin disodium, fosfomycin sodium, fosfomycin trometamol, Article 31 referrals, Procedure started, 13/12/2018

Referral: Fosfomycin-containing medicinal products, fosfomycin calcium, fosfomycin disodium, fosfomycin sodium, fosfomycin trometamol, Article 31 referrals, Procedure started, 13/12/2018

Europe - EMA - European Medicines Agency

27-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): Fibrinogen,thrombin,aprotinin,calcium chloride, decision type: , therapeutic area: , PIP number: P/0199/2018

Opinion/decision on a Paediatric investigation plan (PIP): Fibrinogen,thrombin,aprotinin,calcium chloride, decision type: , therapeutic area: , PIP number: P/0199/2018

Opinion/decision on a Paediatric investigation plan (PIP): Fibrinogen,thrombin,aprotinin,calcium chloride, decision type: , therapeutic area: , PIP number: P/0199/2018

Europe - EMA - European Medicines Agency